Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich

被引：0
|
作者：
Sanoyan, D. Akhoundova [1 ]
Siebenhuner, A. [1 ]
Delaloye, R. [1 ]
Bankel, L. [1 ]
Paulino, T. D. L. [2 ]
Curioni, A. [1 ]
机构：
[1] Univ Hosp Zurich, Med Oncol, Zurich, Switzerland
[2] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
23P
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [41] Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Drilon, A.
    Subbiah, V.
    Gautschi, O.
    Tomasini, P.
    De Braud, F. G. M.
    Solomon, B.
    Tan, D. Shao-Weng
    Alonso, G.
    Wolf, J.
    Park, K.
    Goto, K.
    Soldatenkova, V.
    Szymczak, S.
    Barker, S.
    Puri, T.
    Lin, A. B.
    Loong, H. H. F.
    Besse, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S43 - S43
  • [42] Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Alonso-Garcia, Miriam
    Sanchez-Gastaldo, Amparo
    Munoz-Fuentes, Miguel A.
    Molina-Pinelo, Sonia
    Boyero, Laura
    Benedetti, Johana Cristina
    Bernabe-Caro, Reyes
    PHARMACEUTICALS, 2022, 15 (05)
  • [43] Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
    Besse, Benjamin
    Solomon, Benjamin J.
    Felip, Enriqueta
    Bauer, Todd Michael
    Ou, Sai-Hong Ignatius
    Soo, Ross A.
    Camidge, D. Ross
    Chiari, Rita
    Gadgeel, Shirish M.
    Riely, Gregory J.
    Tan, Eng Huat
    Hayashi, Hidetoshi
    Mazieres, Julien
    Thurm, Holger C.
    Martini, Jean-Francois
    Abbattista, Antonello
    Peltz, Gerson
    Clancy, Jill S.
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis
    Ebi, N.
    Semba, H.
    Tokunaga, S.
    Takayama, K.
    Wataya, H.
    Kuraki, T.
    Yamamoto, H.
    Akamine, S.
    Okamoto, I.
    Nakanishi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience
    Dudnik, E.
    Moskovitz, M.
    Wollner, M.
    Zer, A.
    Bar, J.
    Agbarya, A.
    Idan, T.
    Shechtman, Y.
    Abu Amna, M.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S136 - S136
  • [46] Multicenter real-world study (RWS) on efficacy and early discontinuation predictors in non-small cell lung cancer (NSCLC) patients (pts) receiving nivolumab
    Pasello, G.
    Bortolami, A.
    Tognazzo, S.
    Crivellaro, G.
    Torchia, A.
    Lorenzi, M.
    Menis, J.
    Frega, S.
    Bonanno, L.
    Guarneri, V.
    Conte, P. F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S796 - S796
  • [47] Sex influence on cancer immunotherapy efficacy and safety in advanced non-small cell lung cancer (NSCLC): A Canadian institution real-world experience
    Cohen, Sara Frida
    Cruiziat, Diane
    Naimer, Jeremy
    Cohen, Victor
    Kasymjanova, Goulnar
    Spatz, Alan
    Agulnik, Jason Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
    Zhong, Yuejiao
    Wei, Qiang
    Lu, You
    Tang, Xiuliang
    Wang, Zhongqiu
    Chen, Lingxiang
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6016 - 6022
  • [49] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Schmid, S.
    Diem, S.
    Krapf, M.
    Li, Q.
    Flatz, L.
    Leschka, S.
    Desbiolles, L.
    Klingbiel, D.
    Jochum, W.
    Fruh, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2420
12345